Antipneumococcal Activity of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin
Open Access
- 1 May 2005
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (5) , 1932-1942
- https://doi.org/10.1128/aac.49.5.1932-1942.2005
Abstract
Ceftobiprole (previously known as BAL9141), an anti-methicillin-resistant Staphylococcus aureus cephalosporin, was very highly active against a panel of 299 drug-susceptible and -resistant pneumococci, with MIC 50 and MIC 90 values (μg/ml) of 0.016 and 0.016 (penicillin susceptible), 0.06 and 0.5 (penicillin intermediate), and 0.5 and 1.0 (penicillin resistant). Ceftobiprole, imipenem, and ertapenem had lower MICs against all pneumococcal strains than amoxicillin, cefepime, ceftriaxone, cefotaxime, cefuroxime, or cefdinir. Macrolide and penicillin G MICs generally varied in parallel, whereas fluoroquinolone MICs did not correlate with penicillin or macrolide susceptibility or resistance. All strains were susceptible to linezolid, quinupristin-dalfopristin, daptomycin, vancomycin, and teicoplanin. Time-kill analyses showed that at 1× and 2× the MIC, ceftobiprole was bactericidal against 10/12 and 11/12 strains, respectively. Levofloxacin, moxifloxacin, vancomycin, and teicoplanin were each bactericidal against 10 to 12 strains at 2× the MIC. Azithromycin and clarithromycin were slowly bactericidal, and telithromycin was bactericidal against only 5/12 strains at 2× the MIC. Linezolid was mainly bacteriostatic, whereas quinupristin-dalfopristin and daptomycin showed marked killing at early time periods. Prolonged serial passage in the presence of subinhibitory concentrations of ceftobiprole failed to yield mutants with high MICs towards this cephalosporin, and single-passage selection showed very low frequencies of spontaneous mutants with breakthrough MICs towards ceftobiprole.Keywords
This publication has 48 references indexed in Scilit:
- Global distribution of Streptococcus pneumoniae serotypes isolated from paediatric patients during 1999–2000 and the in vitro efficacy of telithromycin and comparatorsJournal of Medical Microbiology, 2004
- In Vitro Antimicrobial Susceptibilities of Streptococcus pneumoniae Clinical Isolates Obtained in Canada in 2002Antimicrobial Agents and Chemotherapy, 2004
- Efficacy of BAL5788, a Prodrug of Cephalosporin BAL9141, in a Mouse Model of Acute Pneumococcal PneumoniaAntimicrobial Agents and Chemotherapy, 2004
- In vitro activity of BAL9141 against clinical isolates of gram-negative bacteriaDiagnostic Microbiology and Infectious Disease, 2004
- Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocciJournal of Antimicrobial Chemotherapy, 2003
- High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniaeJournal of Antimicrobial Chemotherapy, 2003
- Linezolid in vitro: mechanism and antibacterial spectrumJournal of Antimicrobial Chemotherapy, 2003
- Fluoroquinolone Resistance inStreptococcus pneumoniaeNew England Journal of Medicine, 1999
- Penicillin-resistant Streptococcus pneumoniae in acute otitis mediaThe Pediatric Infectious Disease Journal, 1995
- Management of penicillin-resistant pneumococcal infectionsThe Pediatric Infectious Disease Journal, 1992